Efficacy of Secukinumab

Secukinumab, used to treat psoriasis, ankylosing spondylitis and psoriatic arthritis, is administered by subcutaneous injection, sold in prefilled syringes or auto-injectors for use at home, and as a lyophilized powder for use in hospitals and clinics. Secukinumab should not be used in patients with active infection because it suppresses the immune system.

Secukinumab is a fully human monoclonal IgG1/K antibody directed against interleukin-17A (IL-17A). IL-17A is a member of IL-17 and has the most prominent role in host defense and autoimmunity. IL-17A is commonly upregulated in several autoimmune diseases, such as psoriatic arthritis, rheumatoid arthritis, and ankylosing spondylitis, making it an important therapeutic target. IL-17A is also more potent than another member of IL-17, IL-17F, and has greater affinity for the IL-17 receptor. Secukinumab selectively binds and inhibits IL-17A, preventing its interaction with and activation of the IL-17 receptor.

Secukinumab The original drug has been launched in China and has entered the scope of Class B medical insurance. However, domestic patients who can purchase this drug are limited to eligible patients with psoriasis and ankylosing spondylitis. Patients who are not eligible for medical insurance reimbursement can only purchase it at their own expense. The price of each box of 150mg/ML is about RMB 1,000. SecukinumabThe original drug has also been launched overseas. The specifications of the Turkish original versionThe price per box of 150mg/ML is about 1,500 yuan, and the European version is 150m. The price of each box of g/ML*2 is around RMB 15,000 (the price may fluctuate due to the exchange rate). The ingredients of foreign original drugs and domestic original drugs are basically the same. Currently, there are no generic secukinumab drugs on the market.